1
|
Ivanova N, Leite ALJ, Vieira MB, Silva OHCE, Mota LWR, Costa GDP, de Azevedo CS, Auharek SA, Novaes RD, Pinto KMDC, Bianchi RF, Talvani A. New Insights Into Blue Light Phototherapy in Experimental Trypanosoma cruzi Infection. Front Cell Infect Microbiol 2021; 11:673070. [PMID: 34722326 PMCID: PMC8549511 DOI: 10.3389/fcimb.2021.673070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2021] [Accepted: 04/27/2021] [Indexed: 11/13/2022] Open
Abstract
The search for an effective etiologic treatment to eliminate Trypanosoma cruzi, the causative agent of Chagas disease, has continued for decades and yielded controversial results. In the 1970s, nifurtimox and benznidazole were introduced for clinical assessment, but factors such as parasite resistance, high cellular toxicity, and efficacy in acute and chronic phases of the infection have been debated even today. This study proposes an innovative strategy to support the controlling of the T. cruzi using blue light phototherapy or blue light-emitting diode (LED) intervention. In in vitro assays, axenic cultures of Y and CL strains of T. cruzi were exposed to 460 nm and 40 µW/cm2 of blue light for 5 days (6 h/day), and parasite replication was evaluated daily. For in vivo experiments, C57BL6 mice were infected with the Y strain of T. cruzi and exposed to 460 nm and 7 µW/cm2 of blue light for 9 days (12 h/day). Parasite count in the blood and cardiac tissue was determined, and plasma interleukin (IL-6), tumoral necrosis factor (TNF), chemokine ligand 2 (CCL2), and IL-10 levels and the morphometry of the cardiac tissue were evaluated. Blue light induced a 50% reduction in T. cruzi (epimastigote forms) replication in vitro after 5 days of exposure. This blue light-mediated parasite control was also observed by the T. cruzi reduction in the blood (trypomastigote forms) and in the cardiac tissue (parasite DNA and amastigote nests) of infected mice. Phototherapy reduced plasma IL-6, TNF and IL-10, but not CCL2, levels in infected animals. This non-chemical therapy reduced the volume density of the heart stroma in the cardiac connective tissue but did not ameliorate the mouse myocarditis, maintaining a predominance of pericellular and perivascular mononuclear inflammatory infiltration with an increase in polymorphonuclear cells. Together, these data highlight, for the first time, the use of blue light therapy to control circulating and tissue forms of T. cruzi. Further investigation would demonstrate the application of this promising and potential complementary strategy for the treatment of Chagas disease.
Collapse
Affiliation(s)
- Natália Ivanova
- Laboratório de Imunobiologia da Inflamação, Departamento de Ciências Biológicas, Instituto de Ciências Exatas e Biológicas (ICEB), Universidade Federal de Ouro Preto, Ouro Preto, Brazil.,Programa de Pós Graduação em Ecologia de Biomas Tropicais, Universidade Federal de Ouro Preto, Ouro Preto, Brazil
| | - Ana Luísa Junqueira Leite
- Laboratório de Imunobiologia da Inflamação, Departamento de Ciências Biológicas, Instituto de Ciências Exatas e Biológicas (ICEB), Universidade Federal de Ouro Preto, Ouro Preto, Brazil
| | - Marcel Barbosa Vieira
- Laboratório de Polímerose Propriedades Eletrônicas de Materiais, Departamento de Física, ICEB, Universidade Federal de Ouro Preto, Ouro Preto, Brazil
| | - Otto Henrique Cezar E Silva
- Laboratório de Polímerose Propriedades Eletrônicas de Materiais, Departamento de Física, ICEB, Universidade Federal de Ouro Preto, Ouro Preto, Brazil
| | - Ludmilla Walter Reis Mota
- Laboratório de Imunobiologia da Inflamação, Departamento de Ciências Biológicas, Instituto de Ciências Exatas e Biológicas (ICEB), Universidade Federal de Ouro Preto, Ouro Preto, Brazil
| | - Guilherme de Paula Costa
- Laboratório de Imunobiologia da Inflamação, Departamento de Ciências Biológicas, Instituto de Ciências Exatas e Biológicas (ICEB), Universidade Federal de Ouro Preto, Ouro Preto, Brazil.,Programa de Pós-graduação em Saúde e Nutrição, Universidade Federal de Ouro Preto, Ouro Preto, Brazil
| | | | - Sarah Alves Auharek
- Faculdade de Medicina do Mucuri, Universidade Federal dos Vales do Jequitinhonha e Mucuri, Teofilo Otoni, Brazil
| | - Romulo Dias Novaes
- Departamento de Biologia Estrutural, Universidade Federal de Alfenas, Alfenas, Brazil
| | - Kelerson Mauro de Castro Pinto
- Laboratório de Imunobiologia da Inflamação, Departamento de Ciências Biológicas, Instituto de Ciências Exatas e Biológicas (ICEB), Universidade Federal de Ouro Preto, Ouro Preto, Brazil.,Escola de Educação Física, Universidade Federal de Ouro Preto, Ouro Preto, Brazil
| | - Rodrigo Fernando Bianchi
- Laboratório de Polímerose Propriedades Eletrônicas de Materiais, Departamento de Física, ICEB, Universidade Federal de Ouro Preto, Ouro Preto, Brazil
| | - André Talvani
- Laboratório de Imunobiologia da Inflamação, Departamento de Ciências Biológicas, Instituto de Ciências Exatas e Biológicas (ICEB), Universidade Federal de Ouro Preto, Ouro Preto, Brazil.,Programa de Pós Graduação em Ecologia de Biomas Tropicais, Universidade Federal de Ouro Preto, Ouro Preto, Brazil.,Programa de Pós-graduação em Saúde e Nutrição, Universidade Federal de Ouro Preto, Ouro Preto, Brazil.,Programa de Pós-graduação em Infectologia e Medicina Tropical, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| |
Collapse
|
2
|
Panahi M, Vadgama N, Kuganesan M, Ng FS, Sattler S. Immunopharmacology of Post-Myocardial Infarction and Heart Failure Medications. J Clin Med 2018; 7:E403. [PMID: 30384415 PMCID: PMC6262592 DOI: 10.3390/jcm7110403] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2018] [Revised: 10/23/2018] [Accepted: 10/29/2018] [Indexed: 12/15/2022] Open
Abstract
The immune system responds to acute tissue damage after myocardial infarction (MI) and orchestrates healing and recovery of the heart. However, excessive inflammation may lead to additional tissue damage and fibrosis and exacerbate subsequent functional impairment, leading to heart failure. The appreciation of the immune system as a crucial factor after MI has led to a surge of clinical trials investigating the potential benefits of immunomodulatory agents previously used in hyper-inflammatory conditions, such as autoimmune disease. While the major goal of routine post-MI pharmacotherapy is to support heart function by ensuring appropriate blood pressure and cardiac output to meet the demands of the body, several drug classes also affect a range of immunological pathways and modulate the post-MI immune response, which is crucial to take into account when designing future immunomodulatory trials. This review outlines how routine post-MI pharmacotherapy affects the immune response and may thus influence post-MI outcomes and development towards heart failure. Current key drug classes are discussed, including platelet inhibitors, statins, β-blockers, and renin⁻angiotensin⁻aldosterone inhibitors.
Collapse
Affiliation(s)
- Mona Panahi
- National Heart and Lung Institute, Imperial College London, London W12 0NN, UK.
| | - Nimai Vadgama
- National Heart and Lung Institute, Imperial College London, London W12 0NN, UK.
| | - Mathun Kuganesan
- University College London Medical School, University College London, London WC1E 6BT, UK.
| | - Fu Siong Ng
- National Heart and Lung Institute, Imperial College London, London W12 0NN, UK.
| | - Susanne Sattler
- National Heart and Lung Institute, Imperial College London, London W12 0NN, UK.
| |
Collapse
|
3
|
Horta AL, Figueiredo VP, Leite ALJ, Costa GDP, Menezes APDJ, Ramos CDO, Pedrosa TCF, Bezerra FS, Vieira PMDA, Talvani A. The β-blocker carvedilol and the benznidazole modulate the cardiac immune response in the acute infection induced by Colombian strain of the Trypanosoma cruzi. Mem Inst Oswaldo Cruz 2018; 113:e180271. [PMID: 30365644 PMCID: PMC6193372 DOI: 10.1590/0074-02760180271] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2018] [Accepted: 09/27/2018] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND The infection led by Trypanosoma cruzi persists in mammalian tissues causing an inflammatory imbalance. Carvedilol (Cv), a non-selective beta blocker drug indicated to treat heart failure and antihypertensive has shown to promote antioxidant and immunomodulatory properties which might improve the inflammation induced by T. cruzi. OBJECTIVES Evaluate the role of Cv on the inflammatory response of C57BL/6 mice acutely infected with the Colombian strain of T. cruzi. METHODS Animals were infected with the Colombian strain of T. cruzi and treated with Cv (25 mg/kg/day), benznidazole (Bz) (100 mg/kg/day) or their combination. On the 28th day of infection and 23 days of treatment, the euthanasia occurred, and the heart preserved for histopathological, oxidative stress (SOD, catalase, TBARs, carbonylated proteins) and plasma (CCL2, CCL5, TNF, IL-10) analyses. Parasitaemia and survival were assessed along the infection. FINDINGS Cv decreased TBARs, but increased the mortality rate, the parasitaemia and the levels of CCL2, CCL5, catalase and the inflammatory infiltrate in the cardiac tissue. Bz led the reduction of the inflammatory infiltrate and circulating levels of oxidative stress and inflammatory mediators in the infected mice. MAIN CONCLUSIONS Our data suggest that Cv, in this experimental model using the Colombian strain of T. cruzi, caused damage to the host.
Collapse
Affiliation(s)
- Aline Luciano Horta
- Universidade Federal de Ouro Preto, Departamento de Ciências Biológicas, Ouro Preto, MG, Brasil.,Universidade Federal de Ouro Preto, Programa de Pós-Graduação em Ciências Biológicas, Ouro Preto, MG, Brasil
| | - Vivian Paulino Figueiredo
- Universidade Federal de Ouro Preto, Departamento de Ciências Biológicas, Ouro Preto, MG, Brasil.,Universidade Federal de Ouro Preto, Programa de Pós-Graduação em Ciências Biológicas, Ouro Preto, MG, Brasil
| | - Ana Luisa Junqueira Leite
- Universidade Federal de Ouro Preto, Departamento de Ciências Biológicas, Ouro Preto, MG, Brasil.,Universidade Federal de Ouro Preto, Programa de Pós-Graduação em Ciências Biológicas, Ouro Preto, MG, Brasil
| | - Guilherme de Paula Costa
- Universidade Federal de Ouro Preto, Departamento de Ciências Biológicas, Ouro Preto, MG, Brasil.,Universidade Federal de Ouro Preto, Programa de Pós-Graduação em Ciências Biológicas, Ouro Preto, MG, Brasil
| | - Ana Paula de Jesus Menezes
- Universidade Federal de Ouro Preto, Departamento de Ciências Biológicas, Ouro Preto, MG, Brasil.,Universidade Federal de Ouro Preto, Programa de Pós-Graduação em Ciências Biológicas, Ouro Preto, MG, Brasil
| | - Camila de Oliveira Ramos
- Universidade Federal de Ouro Preto, Departamento de Ciências Biológicas, Ouro Preto, MG, Brasil.,Universidade Federal de Ouro Preto, Programa de Pós-Graduação em Ciências Biológicas, Ouro Preto, MG, Brasil
| | - Tamiles Caroline Fernandes Pedrosa
- Universidade Federal de Ouro Preto, Departamento de Ciências Biológicas, Ouro Preto, MG, Brasil.,Universidade Federal de Ouro Preto, Programa de Pós-Graduação em Ciências Biológicas, Ouro Preto, MG, Brasil
| | - Frank Silva Bezerra
- Universidade Federal de Ouro Preto, Departamento de Ciências Biológicas, Ouro Preto, MG, Brasil.,Universidade Federal de Ouro Preto, Programa de Pós-Graduação em Ciências Biológicas, Ouro Preto, MG, Brasil.,Universidade Federal de Ouro Preto, Programa de Pós-Graduação em Saúde e Nutrição, Ouro Preto, MG, Brasil
| | - Paula Melo de Abreu Vieira
- Universidade Federal de Ouro Preto, Departamento de Ciências Biológicas, Ouro Preto, MG, Brasil.,Universidade Federal de Ouro Preto, Programa de Pós-Graduação em Ciências Biológicas, Ouro Preto, MG, Brasil
| | - André Talvani
- Universidade Federal de Ouro Preto, Departamento de Ciências Biológicas, Ouro Preto, MG, Brasil.,Universidade Federal de Ouro Preto, Programa de Pós-Graduação em Ciências Biológicas, Ouro Preto, MG, Brasil.,Universidade Federal de Ouro Preto, Programa de Pós-Graduação em Saúde e Nutrição, Ouro Preto, MG, Brasil.,Universidade Federal de Ouro Preto, Programa de Pós-Graduação em Biomas Tropicais, Ouro Preto, MG, Brasil
| |
Collapse
|
4
|
Raaz-Schrauder D, Schrauder MG, Stumpf C, Lewczuk P, Kilian T, Dietel B, Garlichs CD, Schlundt C, Achenbach S, Klinghammer L. Plasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk. Heart Vessels 2017; 32:1304-1313. [PMID: 28567553 DOI: 10.1007/s00380-017-0998-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/21/2016] [Accepted: 05/26/2017] [Indexed: 12/29/2022]
Abstract
Osteoprotegerin (OPG) and receptor activator of nuclear factor-κB ligand (RANKL) are regulators of bone remodeling, but are also considered to play important roles in coronary artery disease (CAD). This study evaluated potential associations of soluble (s) RANKL and OPG with atherosclerosis-relevant cytokines. Blood was collected from 414 individuals who presented to our hospital with intermediate likelihood for CAD for further examination. Plasma concentrations of total sRANKL, OPG, and 20 cytokines were measured using sandwich-type enzyme-linked immunoassays (ELISAs; OPG and sRANKL) and Luminex laser-based fluorescence analysis and correlated with each other. The plasma levels of interferon-γ (IFN-γ) and the T-helper cell 2 cytokines interleukin-4 (IL-4) and IL-13 showed a positive correlation with sRANKL. The association with sRANKL levels was negative for IFN-γ-induced protein-10 (IP-10) and monocyte chemotactic protein-1 (MCP-1). The strongest independent association with sRANKL in multivariable analyses was found for IFN-γ (positive) and IP-10 (negative), while IL-13 showed a positive and independent association with OPG plasma levels. OPG and sRANKL plasma levels correlate strongly and independently with specific circulating atherosclerosis-related cytokines in patients with intermediate cardiovascular risk.
Collapse
Affiliation(s)
- Dorette Raaz-Schrauder
- Friedrich-Alexander University Erlangen-Nürnberg (FAU), Department of Cardiology and Angiology, Erlangen University Hospital, Ulmenweg 18, 91054, Erlangen, Germany.
| | - Michael G Schrauder
- Friedrich-Alexander University Erlangen-Nürnberg (FAU), Department of Obstetrics and Gynecology, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - Christian Stumpf
- Friedrich-Alexander University Erlangen-Nürnberg (FAU), Department of Cardiology and Angiology, Erlangen University Hospital, Ulmenweg 18, 91054, Erlangen, Germany
| | - Piotr Lewczuk
- Friedrich-Alexander University Erlangen-Nürnberg(FAU), Department of Psychiatry and Psychotherapy, Erlangen, University Hospital, Erlangen, Germany.,Department of Neurodegeneration Diagnostics, Medical University of Białystok, Białystok, Poland.,Department of Biochemical Diagnostics, University Hospital of Białystok, Białystok, Poland
| | - Tobias Kilian
- Friedrich-Alexander University Erlangen-Nürnberg (FAU), Department of Cardiology and Angiology, Erlangen University Hospital, Ulmenweg 18, 91054, Erlangen, Germany
| | - Barbara Dietel
- Friedrich-Alexander University Erlangen-Nürnberg (FAU), Department of Cardiology and Angiology, Erlangen University Hospital, Ulmenweg 18, 91054, Erlangen, Germany
| | | | - Christian Schlundt
- Friedrich-Alexander University Erlangen-Nürnberg (FAU), Department of Cardiology and Angiology, Erlangen University Hospital, Ulmenweg 18, 91054, Erlangen, Germany
| | - Stephan Achenbach
- Friedrich-Alexander University Erlangen-Nürnberg (FAU), Department of Cardiology and Angiology, Erlangen University Hospital, Ulmenweg 18, 91054, Erlangen, Germany
| | - Lutz Klinghammer
- Friedrich-Alexander University Erlangen-Nürnberg (FAU), Department of Cardiology and Angiology, Erlangen University Hospital, Ulmenweg 18, 91054, Erlangen, Germany
| |
Collapse
|